Metrics as of 10/13/2026, 06:47 PM (Berlin time), refresh in progress.
Inventiva Stock
Inventiva S.A.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- CEO
- Andrew Obenshain
- Employees
- 77
- Market cap
- €153 M
- IPO
- 10/07/2020
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other…
Inventiva stock: price history
1D
-5.8%
1W
-15.1%
1M
-26.9%
6M
-46.7%
YTD
-36.8%
1Y
-36.3%
2Y
+55.4%
5Y
-77.1%
10Y
–
Next earnings date
Next earnings date
31/03/2027 (in 165 days)
Volatility around earnings
~11% stronger price swings than usual
Ask the agents about Inventiva
Analyst assessment of Inventiva
PRICE TARGET LOW
€14.00
CONSENSUS
€14.00
MEDIAN
€14.00
PRICE TARGET HIGH
€14.00
0
STRONG BUY
8
BUY
0
HOLD
1
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 02/10/2026
Inventiva stock metrics
P/E
-4.99
P/B
12.26
EV/EBITDA
-14.07
RETURN ON EQUITY
-119.4%
NET MARGIN
-5,394.8%
DEBT/EQUITY
1.13
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
84.6%
FLOAT SHARES
43,973,293
AVG. DAILY VOLUME (30D)
2,271,350
Institutional holders
Comparable stocks
Frequently asked questions about Inventiva stock
What does Inventiva do?
Inventiva S.A. is a company in the Healthcare sector, Biotechnology industry, headquartered in France.
The CEO is Andrew Obenshain, the company employs around 77 people.
The IPO was on 10/07/2020; the stock trades on NASDAQ under the ticker IVA.
What do analysts say about Inventiva stock?
9 analysts rate the stock, the consensus is Buy (as of 02/10/2026).
The average price target is €14.00, ranging from €14.00 to €14.00, with a median of €14.00.
This is an external assessment, not a statement by Market Jury.
When does Inventiva report next?
The next earnings date is 31/03/2027.
Around past earnings, price swings were roughly 11% stronger than usual.
Does Inventiva pay a dividend?
No, Inventiva currently does not pay a dividend.
Which stocks are comparable to Inventiva?
Comparable stocks include Nanobiotix, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Inventiva stock analyzed?
Clicking "Analyze stock" lets five strategies assess Inventiva against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.